July 5, 2016 / 3:12 PM / a year ago

BRIEF-RedHill Biopharma, IntelGenx announce agreement for commercialization of RIZAPORT

1 Min Read

July 5 (Reuters) - Redhill Biopharma Ltd :

* RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT for migraines with Grupo Juste in Spain and additional potential territories

* Commercial launch in Spain is expected to take place in second half of 2017

* Initial term of deal is for ten years from date of first commercial sale, shall automatically renew for additional two-year term

* Under terms of agreement, RedHill granted Grupo Juste exclusive rights to register and commercialize RIZAPORT in Spain

* Co, IntelGenx entitled to also receive tiered royalties

* Financial terms of agreement were not disclosed

* Co, IntelGenx entitled to receive upfront payment,additional milestone payments upon achievement of predefined regulatory Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below